Mergers & Acquisitions - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

226 to 249 of 249 results

RusNano to start production of vaccines and organogels

09-01-2012

Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

Smith & Nephew to spin-out biologics and clinical therapies unit

05-01-2012

Texas, USA-based venture capital firm Essex Woodlands has entered into a strategic partnership with the…

BiotechnologyBioventusMergers & AcquisitionsSmith & Nephew

Biotech predictions for 2012 from sector specialist Steven Burrill

03-01-2012

As 2011 drew to a close, Steven Burrill, chief executive of global life sciences financial services firm…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegulation

Actelion pulls out of Trophos option

13-12-2011

Switzerland-based Actelion (SIX: ATLN), Europe’s biggest biotech company, says that it has decided…

ActelionBiotechnologyLicensingMergers & AcquisitionsolesoximePharmaceuticalRare diseasesTrophos

US Biotech scores wins in November, despite global economic turmoil, says Burrill

04-12-2011

Economic and political worries in Europe and the USA fuelled another month of wild gyrations in the stock…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaResearch

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

22-11-2011

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Valeant to acquire Australia’s iNova for up to $946 million

22-11-2011

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has signed…

BiotechnologyiNovaMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Angiotech opts out of cardiovascular cell therapy program with Athersys

15-11-2011

Regenerative medicines firm Athersys (Nasdaq: ATHX) says that Canada’s Angiotech Pharmaceuticals…

AngiotechAthersysBiotechnologyFinancialLicensingMergers & Acquisitions

Karo Bio to spin off preclinical development

26-10-2011

In order to achieve better allocation of resources and competences, Swedish biotech firm Karo Bio (STO:…

BiotechnologyKaro BioMergers & AcquisitionsResearch

WuXi PharmaTech acquires China-based clinical services companies; ShangPharma buys Charles River research facility

25-10-2011

WuXi PharmaTech (NYSE: WX) says it has acquired MedKey Med-Tech Development and Jiecheng Med-Tech Development,…

BiotechnologyCharles River LaboratoriesMergers & AcquisitionsPharmaceuticalShangPharmaWuXi Apptec

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports

18-10-2011

Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Angel Biotech proposes joint venture with Russia’s Materia Medica

18-10-2011

Scotland-based Angel Biotechnology (ABH: LON) saw its shares leap 20% to 0.28 pence on Monday after it…

Angel BiotechnologyBiotechnologyEuropeMateria MedicaMergers & Acquisitions

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research

16-10-2011

Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

US biotech sector besieged by debt worries, political dysfunction in 3rd-qtr, says Burrill

06-10-2011

The fight in the USA over the raising of the debt ceiling and the debt crisis in Europe have fueled turmoil…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaRegulation

Contract research firm PPD to go private in $3.9 billion acquisition

04-10-2011

USA-based contact research organization Pharmaceutical Product Development (Nasdaq: PPDI) says it has…

BiotechnologyMergers & AcquisitionsPharmaceuticalPPD

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development

27-09-2011

In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

VBI Vaccines acquires Epixis and its innovative eVLP vaccine platform

16-09-2011

USA-based, privately-held biotechnology company VBI Vaccines said yesterday that it has completed the…

BiotechnologyEpixisMergers & AcquisitionsVaccinesVBI Vaccines

GlaxoSmithKline gets 25% stake in spin-out firm Autifony

23-08-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) has invested £1.25 million ($2.1 million) to receive a…

Autifony TherapeuticsBiotechnologyFinancialGlaxoSmithKlineMergers & Acquisitions

Proteon Thera gets new funding of $15 million, ahead of Novartis acquisition option

15-08-2011

US privately-held biopharmaceutical firm Proteon Therapeutics, the subject of a takeover option by Swiss…

BiotechnologyFinancialMergers & AcquisitionsNovartisPharmaceuticalProteon TherapeuticsResearch

Rusnano and partners set up SynBio innovative pharmaceuticals project in Russia

09-08-2011

Russia’s Human Stem Cells Institute, Rusnano (Russian Corporation of Nanotechnologies), Pharmsynthez,…

BiotechnologyFinancialLipoxenMergers & AcquisitionsRusNanoSymbioTecSynBio

AMAG Pharma and Allos Thera to merge in $686 million stock deal; Express Scripts to buy Medco

21-07-2011

US drugmakers AMAG Pharmaceuticals (Nasdaq: AMAG) and Allos Therapeutics (Nasdaq: ALTH) entered into…

Allos TherapeuticsAMAG PharmaceuticalsBiotechnologyMergers & AcquisitionsPharmaceutical

226 to 249 of 249 results

Back to top